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ABSTRACT
Objectives: To determine whether the prevalence of
chronic kidney disease (CKD) in England has changed
over time.
Design: Cross-sectional analysis of nationally
representative Health Survey for England (HSE) random
samples.
Setting: England 2003 and 2009/2010.
Survey participants: 13 896 adults aged 16+
participating in HSE, adjusted for sampling and
non-response, 2009/2010 surveys combined.
Main outcome measure: Change in prevalence of
estimated glomerular filtration rate (eGFR) <60 mL/min/
1.73 m2 (as proxy for stage 3–5 CKD), from 2003 to
2009/2010 based on a single serum creatinine
measure using an isotope dilution mass spectrometry
traceable enzymatic assay in a single laboratory; eGFR
derived using Modified Diet in Renal Disease (MDRD)
and Chronic Kidney Disease Epidemiology
Collaboration (CKDEPI) eGFR formulae.
Analysis: Multivariate logistic regression modelling to
adjust time changes for sociodemographic and clinical
factors (body mass index, hypertension, diabetes,
lipids). A correction factor was applied to the 2003
HSE serum creatinine to account for a storage effect.
Results: National prevalence of low eGFR (<60)
decreased within each age and gender group for both
formulae except in men aged 65–74. Prevalence of
obesity and diabetes increased in this period, while
there was a decrease in hypertension. Adjustment for
demographic and clinical factors led to a significant
decrease in CKD between the surveyed periods. The
fully adjusted OR for eGFR <60 mL/min/1.73 m2 was
0.75 (0.61 to 0.92) comparing 2009/2010 with 2003
using the MDRD equation, and was similar using the
CKDEPI equation 0.73 (0.57 to 0.93).
Conclusions: The prevalence of a low eGFR indicative
of CKD in England appeared to decrease over this
7-year period, despite the rising prevalence of obesity
and diabetes, two key causes of CKD. Hypertension
prevalence declined and blood pressure control
improved but this did not appear to explain the fall.
Periodic assessment of eGFR and albuminuria in future
HSEs is needed to evaluate trends in CKD.
Strengths and limitations of this study
▪ This study used nationally representative
samples, with later Health Surveys for England
(HSEs) pooled over 2 years to increase the
numbers and precision of estimates. The surveys
used standardised protocols for measurement by
trained interviewers and nurses, with all samples
tested in the same laboratory with standardised
assays.
▪ The analyses enable a longitudinal comparison
of chronic kidney disease (CKD) estimates
across different age–sex groupings and the
application and comparison of the two equations
to derive the estimated glomerular filtration rate
(eGFR). Weighting was introduced for both sur-
veyed periods to reduce response bias and
account for missing data. A correction factor
was applied to the 2003 HSE data to adjust for
the shift in measured creatinine due to sample
storage.
▪ The study was limited by the cross-sectional
nature of the HSE, which restricts the ability to
infer causal relationships from the associations
identified. The study was also limited by the use
of a single sample to test for serum creatinine in
each survey; therefore, the persistence of
reduced eGFR levels to confirm chronicity cannot
be shown.
▪ The prevalence of stage 4/5 CKD is likely to be
underestimated as the HSE may not fully account
for some people in whom more severe CKD
(stage 4/5) will be more common.
▪ The absence of albuminuria data in the 2003
HSE is another major limitation, given its strong
independent association with adverse outcomes
and its use to stratify risk for prevention and
management (eg, use of renin-angiotensin
system inhibition).
Aitken GR, et al. BMJ Open 2014;4:e005480. doi:10.1136/bmjopen-2014-005480 1
Open Access Research
 group.bmj.com on October 17, 2014 - Published by bmjopen.bmj.comDownloaded from 
INTRODUCTION
Chronic kidney disease (CKD) is recognised as a global
public health problem.1 CKD is deﬁned and staged
using the estimated glomerular ﬁltration rate (eGFR)
and markers of kidney damage, mainly albuminuria.2
Both eGFR and albuminuria are strong independent
risk factors for all-cause and cardiovascular disease
(CVD) mortality, and progression to end-stage renal
disease (ESRD), which may require renal replacement
therapy (RRT) by dialysis or transplantation.3 In 2010 in
England, the prevalence of RRT was 832 per million
population, a 3% increase from 2009; the National
Health Service (NHS) costs of RRT were estimated at
£780 million for 2009/2010, and the total cost at £1.45
billion, a nearly threefold increase on estimated costs for
2002.4 5
The population prevalence of CKD in England was
reported for the ﬁrst time using data on eGFR and albu-
minuria in the nationally representative Health Surveys
for England (HSEs) 2009 and 2010, though there had
previously been estimates based on routine testing using
primary care data.6 7 In the combined 2009/2010 HSEs,
6% of men and 7% of women had eGFR <60 mL/min/
1.73 m2 (equivalent to CKD stage 3–5 if chronic) with a
strong age gradient.8 The prevalence of low eGFR
increased in the USA, based on National Health and
Nutrition Examination (NHANES) surveys between 1988
and 2004, even after adjusting for adverse trends in risk
factors (obesity, diabetes, hypertension), but little is
known about CKD prevalence trends in England.9–11
Information on prevalence change is needed to assess
the impact of trends in underlying determinants, and of
strategies to prevent and manage CKD. Several policy
initiatives have been introduced in England that have
had an impact on the prevention, detection and man-
agement of CKD. The National Service Framework for
Renal Services 2004/2005 led to the national reporting
of eGFR by clinical biochemistry laboratories from
2006,12 the General Practice pay for performance
Quality Outcomes Framework (QOF) included targets
for CKD management from 2006/2007,13 and the NHS
Vascular Checks Programme, introduced in 2009,
includes screening for CKD (stage 3–5) in people aged
35–74 with newly identiﬁed type 2 diabetes or hyperten-
sion.14 This study therefore aimed to compare the preva-
lence of CKD in HSE 2003 with the combined 2009/
2010 HSEs and to relate this to any changes in preva-
lence of risk factors for CKD, particularly obesity, dia-
betes and hypertension, over this period.
METHODS
Full details of the conduct of the HSE, and the measure-
ment of non-CKD variables and response rates, are
shown in the 2003 and 2009 Health Survey for England
reports.15 16 Survey participants within private house-
holds were selected using a multistage stratiﬁed random
probability sample. Household response rates were 73%
in HSE 2003 and 68%/66% in HSE 2009/2010. In
co-operating households, 90% and 89%/86% of adults
completed an interview questionnaire while 70% and
62%/57% consented to a nurse visit, of whom 74–76%
provided a blood test. The HSE 2003 contained 18 533
individuals, and data from HSE 2009 and HSE 2010
were combined to provide a sample size of 13 065 indivi-
duals. This totalled 31 598 individuals for the combined
2003, 2009 and 2010 HSEs. Eligible participants were
individuals aged 16 and older who had a valid serum
creatinine value. This left 7850 individuals from the
2003 HSE and 6046 individuals from the combined
2009/2010 HSEs, a total of 13 896 individuals for
analysis.
Age was grouped into ﬁve categories: 16–34, 35–54,
55–64, 65–74 and 75+. There were four separate ethnic
groupings: White, South Asian, Black and Other.
Socioeconomic factors included: (1) occupation—
National Statistics Socio-Economic Classiﬁcation
(NS-SEC, divided into three categories: managerial and
professional occupations, intermediate occupations and
routine and manual occupations); (2) qualiﬁcations
grouped as: degree or equivalent; below degree (other
qualiﬁcation) and none (no qualiﬁcation); (3) house-
hold tenure (own vs renting) and (4) access to motor
vehicle (none vs any).
Smoking status was deﬁned as current, ex-smoker or
never smoked. Hypertension was deﬁned as doctor-
diagnosed (pre-existing diagnosis), survey-deﬁned (iden-
tiﬁed as having high blood pressure (BP, systolic
≥140 mm Hg and/or diastolic ≥90 mm Hg and/or
taking medication for hypertension) at the survey exam-
ination), and ‘total’ (doctor+survey diagnosed).
Survey-deﬁned diabetes was glycated haemoglobin
(HBA1c) ≥6.5% at nurse visit. HBA1c data are presented
for those with and without diagnosed diabetes. Body
mass index (BMI) was deﬁned as normal (<25 kg/m2),
overweight (≥25 and <30 kg/m2) and obese (≥30 kg/m2).
Waist circumference was classiﬁed as: <94, 94–102 (high)
and>102 cm (very high) for men, and <80, 80–88 (high)
and >88 cm (very high) for women. For South Asian
men, the waist circumference was classiﬁed as: <90, 90–
102 (high) and >102 cm (very high). High-density
lipoprotein (HDL) cholesterol and total cholesterol
were treated as continuous variables.
To investigate medication use, we examined the use of
diuretics, β-blockers, renin-angiotensin system (RAS)
inhibitors (ACE inhibitors and angiotensin receptor
blockers (ARBs)), calcium-channel blockers, other anti-
hypertensives in those with doctor-diagnosed hyperten-
sion, doctor-diagnosed diabetes and eGFR <60 mL/
min/1.73 m2, and use of lipid lowering drugs (the
majority of which are statins) in the whole population.
In 2003, 47% of respondents answered yes to whether
they were taking any prescribed medication, and 50% in
2009/2010.
Serum creatinine was assayed using an isotope dilution
mass spectrometry (IDMS) traceable enzymatic assay in
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a single laboratory (Clinical Biochemistry Department at
the Royal Victoria Inﬁrmary, Newcastle Upon Tyne).
Both the Modiﬁed Diet in Renal Disease (MDRD) equa-
tion (in routine use in the UK) and the newer Chronic
Kidney Disease Epidemiology Collaboration (CKDEPI)
equation (which provides better risk prediction and is
recommended for use in international guidelines) were
used to deﬁne CKD.2 17 eGFR values were derived using
the standard equations.18 19
Details of laboratory analysis, internal quality control
and external quality assurance are provided in the HSE
2009/2010 documentation, with these methods repli-
cated in analysis of the 2003 HSE samples.8
Samples were assayed for serum creatinine over a
19-month period with two different batches of the tri-
level Internal Quality Control (IQC) material. HSE 2009
and 2010 samples were analysed with Batch 1 or Batch 2
IQC, while HSE 2003 samples were analysed with Batch
2 IQC. The creatinine assay was stable over time with
IQC results very close to the expected target values.
Batch 1 IQC gave mean (SD) creatinine concentrations
of 56 (0.6), 167 (1.3) and 586 (4.9) μmol/L for levels 1,
2 and 3, respectively, compared with target means of 56,
167 and 588 μmol/L. Batch 2 material gave mean(SD)
creatinine concentrations of 51 (1.1), 175 (2.2) and 597
(5.6) μmol/L for levels 1, 2 and 3, respectively, com-
pared with target means of 51, 175 and 599 μmol/L.
The HSE 2003 samples had been stored, frozen at
−40°C, and then thawed for measurement in 2010.
Although such freezing is not thought to affect creatinine
levels,20 we undertook a reanalysis in 2014 of a random
sample of 500 serum creatinine samples taken from the
2009 HSE and subsequently frozen and stored under the
same conditions as the HSE 2003 samples, stratiﬁed by
quintile, to determine if there was a shift in measured cre-
atinine on storage. We found that mean serum creatinine
increased on storage and was best predicted by a regres-
sion equation where the original 2009 serum creatinine
value without storage equalled 0.303 plus 0.94 multiplied
by the stored serum creatinine value. We assumed that
the same effect applied to the 2003 serum creatinine
data which were analysed in 2009–2010, and we applied
the same adjustment. This decreased the 2003 serum cre-
atinine values. eGFR was classiﬁed as below 60 mL/min/
1.73 m2 or equal to or greater than 60 mL/min/1.73 m2.
We compared the change in mean serum creatinine in
people aged 20–39 without any diabetes or any hyperten-
sion as per Coresh et al.9
STATISTICS
Patient characteristics were compared between the 2003
and 2009/2010 HSEs using χ2 tests for categorical
variables and Mann-Whitney U tests for non-normally
distributed continuous variables. eGFR <60 mL/min/
1.73 m2 prevalence in 2003 and 2009/2010 was
compared across age and sex groupings. BP levels were
compared in all participants, in those with diagnosed
hypertension and in those with eGFR <60 mL/min/
1.73 m2; HBA1c was compared in all participants and in
those with doctor-diagnosed diabetes. Binary logistic
regression models were used to examine the relation-
ships between eGFR <60 mL/min/1.73 m2 and age, sex
and socioeconomic and clinical factors to determine if
there were signiﬁcant differences between the two
survey periods. The dependent variables were CKDEPI
and the MDRD equation eGFR <60 mL/min/1.73 m2
(indicative of stage 3–5 CKD). Four models were pro-
duced for each: (1) age–sex adjusted; (2) model 1 plus
socioeconomic status and ethnicity; (3) model 2 plus
behavioural, lipid levels (HDL and total cholesterol)
and clinical variables except hypertension and (4)
model 3 plus doctor-diagnosed hypertension.
Interactions between period and both diabetes and
hypertension were tested.
Sensitivity analyses were performed by replacing
doctor-diagnosed diabetes with HBA1c, replacing
doctor-diagnosed hypertension with diastolic and systolic
BP and adjusting for lipid lowering agents in the full
model. Non-response and blood sample weights were
used in all analyses to address issues with missing indivi-
duals who did not have a blood sample taken and sent
to the laboratory for analysis to determine the serum
creatinine value. Full details on how the weights were
obtained are provided in the ﬁnal volume of the HSE
report each year. The age, education and smoking status
of those interviewed, having a nurse visit and having a
blood test is similar once non-response is taken into
account (data not shown). All analyses were performed
using IBM SPSS Statistics V.20.
RESULTS
The ﬁnal sample for the study comprised 13 896 indivi-
duals aged 16+ who had a valid serum creatinine value.
Comparing the characteristics of these participants
between the 2003 and 2009/2010 surveys, the age struc-
ture, gender, NS-SEC and car ownership were similar
while the educational level improved and there was an
increase in rented tenure (table 1). The prevalence of
diabetes however classiﬁed increased, as did obesity. In
contrast, smoking and hypertension prevalence
decreased.
There were signiﬁcant increases in BMI, waist circum-
ference and HBA1c in the population, although there
was no change in HBA1c in those with diagnosed dia-
betes (table 2). Median BP levels (systolic and diastolic)
fell in all groups including those with diagnosed hyper-
tension, doctor-diagnosed diabetes and eGFR <60 mL/
min/1.73 m2. Median total and HDL cholesterol fell in
men and women.
The distribution of serum creatinine is similar for
2003 and 2009/2010 (ﬁgure 1). Median serum creatin-
ine increased slightly, leading to a very small non-
signiﬁcant decrease in median eGFR using MDRD and
CKDEPI formulae (table 2). Mean serum creatinine for
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Table 1 Comparison of prevalence of categorical measures in 2003 and 2009/2010*
2003 2009–2010 χ2 Test
Variable Category Number Per cent Number Per cent p Value
All Aged 16+ 7850† 100.0 6046† 100.0 −
Age 16–34 2425 31.0 1847 30.6 0.44
34–54 2790 35.7 2129 35.3
55–64 1126 14.4 886 14.7
65–74 813 10.4 639 10.6
75+ 662 8.5 539 8.9
Missing 0 – 0 –
Ethnicity White 7226 92.5 5244 90.7 <0.001
South Asian 332 4.3 243 4.2
Black 144 1.8 154 2.7
Other 108 1.4 139 2.4
Missing 0 – 0 –
Sex Male 3795 48.6 2961 49.0 0.80
Female 4020 51.4 3080 51.0
Missing 0 – 0 –
Qualification Degree 1375 17.6 1295 22.5 <0.001
Below degree 4551 58.3 3296 57.0
None 1874 24.0 1191 20.6
Missing 11 – 3 –
NS-SEC Highest 2514 33.7 1894 34.8 0.43
Middle 1674 22.4 1203 22.1
Lowest 3273 43.9 2343 43.1
Missing 350 – 345 –
Car ownership Yes 6460 82.7 4728 81.7 0.17
No 1348 17.3 1056 18.3
Missing 2 – 1 –
Tenure Own 5878 75.4 3955 68.5 <0.001
Rent 1914 24.6 1817 31.5
Missing 11 – 13 –
Smoking Current 1960 25.2 1210 21.0 <0.001
Ex 1877 24.1 1429 24.8
Never 3951 50.7 3126 54.2
Missing 22 – 20 –
Body mass index Normal/underweight (<25 kg/m2) 2867 39.2 1956 36.8 <0.001
Overweight (25–30 kg/m2) 2868 39.2 2047 38.5
Obese (>30 kg/m2) 1587 21.7 1314 24.7
Missing 489 – 469 –
Waist circumference Low (<94 cm male, <80 cm female) 3060 39.8 2120 37.1 <0.001
High (94–102 cm male, 80–88 cm female) 1929 25.1 1347 23.6
Very High (>102 cm male, >88 cm female) 2703 35.1 2242 39.3
Missing 118 – 77 –
Doctor-diagnosed diabetes Yes 305 3.9 322 5.3 <0.001
No 7504 96.1 5715 94.7
Missing 6 – 2 –
Survey-diagnosed diabetes Yes (HBA1c ≥6.5%) 296 3.8 316 5.5 <0.001
No (HBA1c <6.5%) 7401 96.2 5417 94.5
Missing 113 – 52 –
Total diabetes Yes 406 5.2 446 7.4 <0.001
No 7405 94.8 5585 92.6
Missing 0 – 0 –
Doctor-diagnosed hypertension Yes 2118 27.2 1501 25.0 0.003
No 5662 72.8 4527 75.0
Missing 36 – 10 –
Survey-diagnosed hypertension Yes 2065 31.5 1545 29.2 0.02
No 4499 68.5 3744 70.8
Missing 1246 – 496 –
Continued
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those aged 20–39 without doctor-diagnosed hyperten-
sion or diabetes increased slightly from 70.6 μmol/L
(SD±13.6) in 2003 to 71.4 μmol/L (SD±14.3) in 2009/
2010 (p=0.09).
The proportion of individuals with MDRD
eGFR<60 mL/min/1.73 m2 decreased from 6.7% in
2003 to 6% in 2009/2010 (p=0.13) and in those with
eGFR <45 mL/min/1.73 m2 from 1.9% to 1.4%
(p=0.03). The corresponding ﬁgures for CKDEPI were
5.7% and 5.2% (p=0.26) and 1.8% and 1.4% (p=0.07),
respectively. The prevalence of low eGFR fell in all age
and gender groups and with either CKDEPI or MDRD
equations, except in men aged 65–74 in whom there was
a slight increase (ﬁgure 2).
Table 1 Continued
2003 2009–2010 χ2 Test
Variable Category Number Per cent Number Per cent p Value
Total hypertension Yes 2866 36.7 2062 34.2 0.004
No 4933 63.3 3968 65.8
Missing 12 – 0 –
eGFR CKDEPI <45 (mL/min/1.73 m2) 142 1.8 81 1.4 0.07
<60 (mL/min/1.73 m2) 444 5.7 303 5.2 0.26
Missing 0 – 0 –
eGFR MDRD <45 (mL/min/1.73 m2) 146 1.9 80 1.4 0.03
<60 (mL/min/1.73 m2) 521 6.7 349 6.0 0.13
Missing 0 – 0 –
Bold typeface indicates significance at p<0.05.
*Weighted for non-response (unless stated otherwise).
†Not weighted.
CKDEPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; HBA1c, glycated haemoglobin;
MDRD, Modified Diet in Renal Disease; NS-SEC, National Statistics Socio-Economic Classification.
Table 2 Weighed comparison of continuous measures in 2003 and 2009–2010
2003 2009–2010 Mann-Whitney U test
Variable Category Median value (IQR) Median value (IQR) p Value
Serum creatinine (μmol/L) Median value 71.7 (62.3–82.1) 72.0 (62.0–83.0) 0.66
eGFR (mL/min/1.73 m2) MDRD 90.5 (77.2–105.4) 90.3 (77.1–104.7) 0.62
CKDEPI 99.3 (84.1–113.9) 98.6 (84.0. –112.5) 0.11
BMI (kg/m2) All 26.2 (23.3–29.4) 26.6 (23.5–30.0) <0.001
Male 26.6 (24.0–29.4) 27.0 (24.2–29.9) 0.001
Female 25.7 (22.7–29.5) 26.1 (23.1–30.0) <0.001
Waist circumference (cm) All 90.6 (81.1–100.0) 92.0 (81.6–101.7) <0.001
Male 95.8 (88.0–104.0) 96.7 (88.2–105.0) 0.05
Female 84.6 (76.4–94.0) 86.3 (77.3–96.7) <0.001
Systolic BP (mm Hg) All 125.5 (115.5–138.0) 124.5 (114.0–136.0) <0.001
Doctor-diagnosed HT 135.5 (124.0–149.5) 134.0 (122.2–145.5) <0.001
Doctor-diagnosed DM 134.5 (122.5–148.0) 131.8 (120.0–143.5) <0.001
eGFR<60 (CKDEPI) 140.2 (126.0–156.0) 131.8 (119.0–143.5) <0.001
eGFR<60 (MDRD) 137.5 (124.0–153.7) 129.2 (118.0–142.5) <0.001
Diastolic BP (mm Hg) All 73.0 (65.5–80.5) 72.5 (65.5–80.) <0.001
Doctor-diagnosed HT 77.5 (70.0–85.5) 76.0 (68.0–83.5) <0.001
Doctor-diagnosed DM 72.0 (64.5–80.5) 71.50 (64.5–78.5) <0.001
eGFR<60 (CKDEPI) 71.5 (62.9–80.5) 68.5 (60.5–76.0) <0.001
eGFR<60 (MDRD) 72.5 (64.0–81.5) 69.0 (61.5–76.8) <0.001
Glycated Hb (%) All 5.20 (5.00–5.50) 5.30 (5.10–5.70) <0.001
Doctor-diagnosed DM 6.90 (5.90–8.20) 6.90 (5.90–8.30) 0.85
HDL cholesterol (mmol/L) All 1.50 (1.20–1.70) 1.40 (1.20–1.70) <0.001
Male 1.30 (1.20–1.60) 1.30 (1.10–1.50) <0.001
Female 1.60 (1.40–1.90) 1.60 (1.30–1.90) 0.046
Total cholesterol (mmol/L) All 5.40 (4.70–6.20) 5.20 (4.40–5.90) <0.001
Male 5.40 (4.70–6.20) 5.10 (4.30–5.90) <0.001
Female 5.40 (4.70–6.20) 5.20 (4.50–6.00) 0.001
Bold typeface indicates significance at p<0.05.
BP, blood pressure; Hb, haemoglobin; CKDEPI, Chronic Kidney Disease Epidemiology Collaboration; DM, diabetes mellitus; eGFR estimated
glomerular filtration rate; HDL, high-density lipoprotein; HT, hypertension; IQR, interquartile range; MDRD, Modified Diet in Renal Disease.
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There was an increase in the mean number of antihyper-
tensive agents taken in individuals with: doctor-diagnosed
hypertension (1.19 in 2003 to 2.01 in 2009/2010), doctor-
diagnosed hypertension and doctor-diagnosed dia-
betes (1.47–2.57); MDRD eGFR <60 mL/min/1.73 m2
(1.30–1.77); and CKDEPI eGFR < 60 mL/min/1.73 m2
(1.35–1.93). The proportion taking RAS inhibitors in indi-
viduals with doctor-diagnosed diabetes, doctor-diagnosed
hypertension, MDRD eGFR <60 mL/min/1.73 m2 or
CKDEPI eGFR <60 mL/min/1.73 m2 also increased, as
did overall lipid lowering agent use (online supplementary
appendix 1).
The age–sex adjusted OR of having low eGFR (MDRD
eGFR <60 mL/min/1.73 m2) in 2009/2010 compared
with 2003 was 0.84 (95% CI 0.72 to 0.98) and fully
adjusted was 0.75 (0.61 to 0.92; table 3). The corre-
sponding ORs for CKDEPI were 0.85 (0.72 to 1.00) and
0.73 (0.57 to 0.93; table 4).
Sensitivity analyses replacing doctor-diagnosed dia-
betes with HBA1c and doctor-diagnosed hypertension
with diastolic and systolic BP made little difference to
the adjusted ORs, as did the inclusion of lipid lowering
agents. No interactions between period and diabetes or
hypertension were identiﬁed.
DISCUSSION
These analyses show that CKD prevalence in England esti-
mated by serum creatinine-based equations in England
appeared to decrease from 2003 to 2009/2010. This
decrease was seen across all age groupings (except in men
Figure 1 Distribution of serum creatinine (μmol/L) for the
2003 and 2009/2010 survey data. Serum creatinine
categories are grouped in bands of 5 μmol/L from 40 μmol/L to
130 μmol/L. Serum creatinine values <40 μmol/L and those
>130 μmol/L are grouped together.
Figure 2 Comparison of low
eGFR (<60 mL/min/1.73 m2)
prevalence difference for MDRD
and CKDEPI equations between
the 2003 and 2009/2010 HSEs
for each age group by gender.
CKD, chronic kidney disease;
CKDEPI, Chronic Kidney Disease
Epidemiology Collaboration;
eGFR estimated glomerular
filtration rate; HSE, Health Survey
for England; MDRD, Modified
Diet in Renal Disease.
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aged 65–74), for CKD deﬁned by MDRD and CKDEPI
eGFR equations was more pronounced for the MDRD
equation and occurred despite the increased prevalence
of diabetes and obesity.21 Using the CKDEPI equation in
place of MDRD to deﬁne CKD resulted in a lower preva-
lence of CKD. While it reduced overall prevalence, the
CKDEPI equation identiﬁed more individuals aged 75+
with CKD compared with the MDRD equation.22 23
Table 3 Prevalence and associations of low eGFR (<60 mL/min/1.73 m2) by MDRD equation with adjustment for
sociodemographic and clinical factors
MDRD
Variable
Prevalence
of CKD (%)† OR (95% CI)‡ OR (95% CI)§ OR (95% CI)¶ OR (95% CI)††
HSE year
2003 6.7 1 1 1 1
2009–2010 6.0 0.84 (0.72 to 0.98)* 0.84 (0.73 to 0.99)* 0.75 (0.61 to 0.92)** 0.75 (0.61 to 0.92)**
Age
16–34 0.2 1 1 1 1
35–54 2.1 10.8 (5.3 to 22.0)** 11.1 (5.5 to 22.8)** 10.8 (5.0 to 23.4)** 10.7 (4.9 to 23.2)**
55–64 6.8 37 (18 to 75)** 36 (18 to 73)** 33 (15 to 72)** 32 (14 to 69)**
65–74 14.5 87 (43 to 175)** 82 (40 to 167)** 65 (30 to 143)** 62 (28 to 135)**
75+ 35.6 276 (138 to 555)** 247 (122 to 501)** 216 (99 to 470)** 202 (93 to 440)**
Sex
Male 5.0 1 1 1 1
Female 7.7 1.42 (1.22 to 1.65)** 1.37 (1.17 to 1.60)** 1.69 (1.36 to 2.10)** 1.66 (1.34 to 2.06)**
Ethnic
White 6.8 – 1 1 1
South Asian 1.7 – 0.83 (0.43 to 1.59) 0.73 (0.33 to 1.60) 0.71 (0.32 to 1.56)
Black 1.7 – 0.38 (0.15 to 1.00) 0.33 (0.09 to 1.19) 0.32 (0.09 to 1.16)
Other 1.6 – 0.81 (0.29 to 2.30) 0.64 (0.17 to 2.46) 0.64 (0.17 to 2.44)
Tenure
Own 6.3 – 1 1 1
Rent 6.6 – 1.34 (1.11 to 1.60)** 1.23 (0.97 to 1.57) 1.23 (0.96 to 1.56)
Education
Degree level 2.4 – 1 1 1
Below degree 4.4 – 1.31 (0.99 to 1.74) 1.15 (0.83 to 1.60) 1.20 (0.84 to 1.70)
None 14.9 – 1.52 (1.13 to 2.04)** 1.20 (0.84 to 1.70) 1.23 (0.96 to 1.57)
Smoking
Never 6.1 – – 1 1
Ex-smoker 10.1 – – 1.17 (0.91 to 1.49) 1.15 (0.85 to 1.54)
Current smoker 3.2 – – 1.02 (0.75 to 1.38) 1.04 (0.80 to 1.40)
BMI (kg/m2)
Normal (<25) 3.4 – – 1 1
Overweight (25–30) 6.6 – – 1.16 (0.91 to 1.49) 1.15 (0.90 to 1.47)
Obese (>30) 8.4 – – 1.31 (0.99 to 1.71) 1.26 (0.96 to 1.65)
HDL cholesterol
Continuous – – – 0.51 (0.38 to 0.67)** 0.51 (0.38 to 0.68)**
Total cholesterol
Continuous – – – 0.91 (0.84 to 1.00) 0.92 (0.84 to 1.00)
Doctor-diagnosed diabetes
No 5.9 – – 1 1
Yes 17.3 – – 1.42 (0.92 to 2.22) 1.36 (0.87 to 2.11)
Doctor-diagnosed hypertension
No 4.0 – – – 1
Yes 13.3 – – – 1.27 (1.03 to 1.55)*
*p<0.05; **p<0.01.
†Prevalence for the combined 2003 and 2009–2010 HSEs.
‡Adjusted for age and sex.
§Adjusted for age, sex, ethnicity, tenure and education.
¶Adjusted for age, sex, ethnicity, tenure, education, smoking, BMI, HDL cholesterol, total cholesterol and doctor-diagnosed diabetes.
††Adjusted for age, sex, ethnicity, tenure, education, smoking, BMI, HDL cholesterol, total cholesterol, doctor-diagnosed diabetes and
doctor-diagnosed hypertension.
BMI, body mass index; CKD, chronic kidney disease; eGFR estimated glomerular filtration rate; HDL, high-density lipoprotein; HSE, Health
Survey for England; MDRD, Modified Diet in Renal Disease.
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The 2003, 2009 and 2010 HSEs were nationally repre-
sentative samples, with the 2009/2010 data pooled over
2 years to increase the numbers and precision of esti-
mates. The age–sex characteristics of the different study
periods sampled were similar. The surveys used standar-
dised protocols for measurement by trained interviewers
and nurses. All samples were tested in the same labora-
tory with standardised assays. The analyses enable a
Table 4 Prevalence and associations of low eGFR (<60) by CKDEPI equation with adjustment for sociodemographic and
clinical factors
CKDEPI
Variable
Prevalence
of CKD (%)† OR (95% CI)‡ OR (95% CI)§ OR (95% CI)¶ OR (95% CI)††
HSE year
2003 5.7 1 1 1 1
2009–2010 5.2 0.85 (0.72 to 1.00) 0.86 (0.72 to 1.01) 0.73 (0.57 to 0.93)* 0.73 (0.57 to 0.93)*
Age
16–34 0.1 1 1 1 1
35–54 1.0 15.1 (4.5 to 51.4)** 16.1 (4.7 to 55.0)** 13.8 (4.0 to 47.2)** 13.5 (3.9 to 46.5)**
55–64 4.2 67 (20 to 225)** 67 (20 to 227)** 55 (16 to 190)** 52 (15 to 177)**
65–74 12.5 219 (66 to 725)** 219 (65 to 731)** 162 (47 to 553)** 151 (44 to 517)**
75+ 36.8 890 (269 to 2938)** 844 (253 to 2808)** 754 (222 to 2559)** 693 (203 to 2355)**
Sex
Male 4.6 1 1 1 1
Female 6.3 1.15 (0.97 to 1.36) 1.11 (0.93 to 1.31) 1.31 (1.01 to 1.68)* 1.28 (1.00 to 1.65)*
Ethnic
White 5.8 – 1 1 1
South Asian 1.4 – 0.93 (0.43 to 2.00) 0.89 (0.35 to 2.42) 0.85 (0.34 to 2.16)
Black 2.0 – 0.56 (0.23 to 1.39) 0.55 (0.16 to 1.82) 0.53 (0.16 to 1.77)
Other 1.6 – 1.19 (0.40 to 3.56) 1.13 (0.29 to 4.41) 1.13 (0.29 to 4.41)
Tenure
Own 5.3 – 1 1 1
Rent 6.0 – 1.44 (1.19 to 1.75)** 1.29 (0.98 to 1.69) 1.28 (0.97 to 1.69)
Education
Degree level 1.8 – 1 1 1
Below degree 3.6 – 1.36 (0.97 to 1.90) 1.05 (0.69 to 1.58) 1.04 (0.69 to 1.58)
None 13.6 – 1.51 (1.08 to 2.13)* 1.12 (0.76 to 1.66) 1.11 (0.75 to 1.65)
Smoking
Never 5.2 – – 1 1
Ex-smoker 9.0 – – 1.09 (0.77 to 1.55) 1.07 (0.75 to 1.52)
Current smoker 2.6 – – 0.80 (0.70 to 1.41) 0.79 (0.54 to 1.14)
BMI (kg/m2)
Normal (<25) 2.7 – – 1 1
Overweight (25–30) 5.5 – – 1.14 (0.86 to 1.51) 1.12 (0.85 to 1.49)
Obese (>30) 7.2 – – 1.31 (0.96 to 1.80) 1.25 (0.91 to 1.72)
HDL cholesterol
Continuous – – – 0.40 (0.29 to 0.56)** 0.40 (0.29 to 0.57)**
Total cholesterol
Continuous – – – 0.93 (0.84 to 1.04) 0.94 (0.86 to 1.04)
Doctor-diagnosed diabetes
No 5.0 – – 1 1
Yes 16.3 – – 1.55 (0.96 to 2.48) 1.46 (0.91 to 2.35)
Doctor-diagnosed hypertension
No 3.1 – – – 1
Yes 12.3 – – – 1.33 (1.05 to 1.67)**
*p<0.05; **p<0.01.
†Prevalence for the combined 2003 and 2009–2010 HSEs.
‡Adjusted for age and sex.
§Adjusted for age, sex, ethnicity, tenure and education.
¶Adjusted for age, sex, ethnicity, tenure, education, smoking, BMI, HDL cholesterol, total cholesterol and doctor-diagnosed diabetes.
††Adjusted for age, sex, ethnicity, tenure, education, smoking, BMI, HDL cholesterol, total cholesterol, doctor-diagnosed diabetes and
doctor-diagnosed hypertension.
BMI, body mass index; CKD, chronic kidney disease; CKDEPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR estimated
glomerular filtration rate; HDL, high-density lipoprotein; HSE, Health Survey for England.
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longitudinal comparison of CKD estimates across differ-
ent age–sex groupings and the application and compari-
son of the two equations to derive eGFR. We accounted
for the shift in measured creatinine on storage in the
2003 HSE serum creatinine data by introduction of a cor-
rection factor derived from analysis of the effect of
storage using 2009 data. Non-response weighting was
undertaken in the HSE for both surveyed periods to
reduce response bias and account for missing data for
individuals who did not have blood samples taken and
hence had no serum creatinine value. We used the HSE
study design and the non-response weights to provide
national prevalence estimates at each period and
adjusted for a wide range of sociodemographic factors, so
residual confounding due to differences in sample
characteristics is less likely. Moreover, the distribution of
age groupings was similar for both periods; hence, it does
not explain the observed eGFR differences. The ethnic
composition of the surveys changed over time with a
small fall in the white population, but we adjusted for this
change in the analysis.
The study was limited by the cross-sectional nature of
the HSE, which restricts the ability to infer causal rela-
tionships from the associations identiﬁed. However, the
use of new, cross-sectional samples enables the measure-
ment of general population CKD prevalence at different
time points. A single sample was tested for serum cre-
atinine in each survey, and therefore the persistence of
reduced eGFR levels to conﬁrm chronicity cannot be
shown. This is standard practice in national surveys such
as NHANES, whereas studies based on routine testing,
such as the QICKD study, can assess chronicity.24 Given
the individual variation in kidney function, more
extreme values will be averaged out on repeated testing
(regression to the mean), reducing the prevalence of
low eGFR.25 The results may therefore slightly overesti-
mate the prevalence of CKD. There were very few cases
from the key minority ethnic groups to give robust data
on ethnic differences in the prevalence of CKD. South
Asians and black groups have higher rates of renal
replacement but have been found to have a lower preva-
lence of CKD than Caucasians.26 27
The prevalence of stage 4/5 CKD is likely to be under-
estimated as, while the HSE is able to adjust for non-
response among the general population in private
households, it may not fully account for some in whom
more severe CKD (stage 4/5) will be more common.
This includes people who were not able to give a blood
or urine sample because of poor health and those who
did not participate due to concurrent illness or hospital-
isation, as well as those in residential care.
The absence of albuminuria data in the 2003 HSE is a
major limitation, given its strong independent association
with adverse outcomes and its use to stratify risk for pre-
vention and management (eg, use of RAS inhibition).3
We have therefore been unable to estimate changes in
the prevalence of albuminuria per se, in all CKD (stages
1–5), and fully assess prevention and management.
The fall in low prevalence of eGFR could be due to
(1) chance, (2) the artefact of differences in the serum
creatinine measurement, (3) changes in serum creatin-
ine production rather than excretion by the kidney, (4)
residual confounding by differences in sample character-
istics not adjusted for by sample weighting and (5) the
true fall in eGFR. The two sets of samples were analysed
in multiple analytical runs over a 19-month time period,
which could lead to differences in results; however,
during this time period, the internal quality control data
indicate that the assay was accurate when compared with
the assigned target values and stable. We found a storage
artefact on serum creatinine measurement and
accounted for this by the introduction of a correction
factor. A change in serum creatinine over time inde-
pendent of the kidney function could be due to less
muscle mass (leading to lower serum creatinine produc-
tion); there is no evidence for this and it seems unlikely
to have occurred at the population level.
A decline in dietary protein consumption from
cooked meat could also lead to a change in serum cre-
atinine. Statistics from the National Diet and Nutrition
Survey show that meat consumption increased from
2001–2002 to 2008–2010 while protein intake remained
virtually stable over the same period.28 The mean con-
sumption of meat and meat products increased from
154 g/day in 2001–2002 to 194 g/day in 2008–2010;
protein intake contributing to food energy for adults
aged 19+ increased slightly from 16–17% in 2001–2002
to 17–18% in 2008–2010; meat and meat products con-
tributed to 37–38% of all protein intake for adults aged
19–64, with little change compared to 2008–2010.
Cooked meat consumption has been shown to increase
serum creatinine in small case studies of volunteers and
of patients with diabetic nephropathy, and hence
national guidance is to avoid eating cooked meat for
12 h before a blood test for creatinine,29 but this was not
done in HSE.
We used the HSE study design and non-response
weights and adjusted for a wide range of sociodemo-
graphic factors, so residual confounding due to differ-
ences in sample characteristics differences is less likely.
Moreover, the distribution of age groupings was similar
for both periods, so it does not explain the observed
eGFR differences.
Key risk groups for developing CKD are people with
hypertension and/or diabetes, especially if they have
albuminuria. In this study, there was evidence of modest
reductions in the prevalence of hypertension, better
control of hypertension in key groups, and greater use
of RAS inhibitors that have antiproteinuric as well as BP
lowering effects, though the period changes in eGFR
remained after correction for changes in hypertension
prevalence. There is evidence from some studies using
HSE, primary care databases and QOF data,30–32 though
not all,33 of improved hypertension control in the past
decade. However, there are ethnic disparities with
poorer control of BP in Black and South Asians who
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have a higher risk of progression to need RRT.34 The
population salt consumption also fell during the past
decade, which is likely to have inﬂuenced population
BP.35 36 CKD prevalence could also fall if those identi-
ﬁed with moderate CKD were treated more aggressively,
especially those with hypertension and/or albuminuria,
leading to increased eGFR in some people to above
60 mL/min/1.73 m2. The limited HSE data suggest
better BP control and greater use of RAS inhibitors in
those with eGFR <60 mL/min/1.73 m2. Karunaratne
et al examined BP control in those with and without
CKD in a primary care population in Kent and showed
that BP control had improved in patients with CKD over
time pre and post the introduction of QOF and that it
was greater than in non-CKD patients with hypertension.
They also showed increased use of RAS inhibitors and
other antihypertensive agents in patients with CKD.37
There was evidence of increased lipid lowering agent
use (indicative of increased statin use) and a small fall in
population lipid levels. There is some evidence of reno-
protective effects of statins in patients with CKD; A lower
rate of decline in GFR was found in patients with renal
disease who took antilipemic agents.38 In the Heart
Protection Study, the use of the hypolipidemic drug sim-
vastatin reduced the rise in slightly elevated creatinine
over time in participants with diabetes and non-diabetic
CKD.39 In the SHARP trial, allocation of the lipid lower-
ing ezetimibe plus simvastatin in participants not already
on dialysis at randomisation reduced the outcome of
ESRD or a doubling of creatinine with an OR of 0.93,
though this was not statistically signiﬁcant.40 In the
GREACE trial, statin treatment prevented a decline in
renal function in people with high blood lipids and cor-
onary heart disease; patients not treated with statins
showed a 5.2% decrease in creatinine clearance, while
patients treated with statins showed a 4.9% increase in
creatinine clearance.41 However, our period changes
were not altered by adjusting for statins (lipid lowering
drugs) or lipid levels (HDL, total cholesterol).37
There are limited data from other countries with
which to compare these ﬁndings. Coresh et al analysed
the US NHANES surveys of 1988–1994 and 1999–2004,
both of which collected albuminuria and eGFR data.
The prevalence of albuminuria and MDRD eGFR
<60 mL/min/1.73 m2 increased, the latter from 5.6% to
8.1%.8 The albuminuria increase was explained by
changes in levels of obesity, diabetes and hypertension,
whereas such adjustment only partly explained the fall
in eGFR. Changes in population serum creatinine
explained most of the remainder of the eGFR changes;
this was analysed by comparing the mean serum creatin-
ine in young people aged 20–39 without diabetes or
hypertension and this had increased across the surveys.9
The authors suggested that this rise in serum creatinine
could be either due to residual laboratory assay
differences or changes in dietary protein or muscle
mass. Grams et al showed that prevalence of eGFR
<60 mL/min/1.73 m2 had also increased using the same
survey data when eGFR was estimated using cystatin C, a
marker of kidney function that is independent of muscle
mass, and this was not explained by changes in demog-
raphy, hypertension, diabetes or obesity, suggesting a
true increase in low eGFR.41
We can compare the estimated national CKD preva-
lence for HSE with QOF returns which record diag-
nosed CKD in primary care.42 Prevalence has been
increasing with improvements in detection and record-
ing, and in 2010 it was 4.2%. The ﬁgures are not directly
comparable as comparing a single screened value versus
routine testing with presumed allowance for chronicity,
but this may suggest some underdiagnosis of CKD.
If this change in prevalence in England is true, then
based on the HSE 2003 age–sex-speciﬁc estimates and
2001 and 2011 Census data, the estimated number of
CKD cases (for those aged 16 and over) would be 2.62
million based on the MDRD equation, falling by 0.03
million for 2009/2010. Equivalent ﬁgures for CKDEPI
eGFR <60 mL/min/1.73 m2 are 2.23 million and 0.02
million increase, respectively. The impact of such
changes would be twofold: a consistent pool of patients
at risk of progressing to need RRT; and a contribution
to consistent cardiovascular incidence and mortality.
The former is supported by stabilised acceptance rates
onto RRT in England.4
CONCLUSIONS
The prevalence of a low eGFR appears to have
decreased in England from 2003 to 2009/2010, despite
increases in obesity and diabetes. It is unclear why this
has occurred and it is difﬁcult to infer directly that this
is due to current policies to improve prevention of CKD
and the identiﬁcation and management of people with
CKD. There is a need for repeated national prevalence
estimates to further assess CKD patterns over time,
including measures of albuminuria and of cystatin C,
both of which were available in HSE 2009 and 2010.
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